Pfizer has found a successor for Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own ...

Pfizer, despite pressure from investors to look outside, elevates its cancer chief Chris Boshoff to lead overall R&D.

The drug company had been searching for a new chief scientific officer since July with Mikael Dolsten leaving after 15 years ...

As for his soon-to-be former role, Boshoff will be succeeded by Dr. Roger Dansey, who will serve as the interim chief ...

"Dr Boshoff is the ideal leader to propel Pfizer's R&D engine forward and transform it into a world-leading organisation with ...

Chris Boshoff will replace Mikael Dolsten, who’s stepping down after 15 years leading research at the drugmaker.

Chris Boshoff will take over as Pfizer’s next chief scientific officer as of January 1, replacing Mikael Dolsten who led the ...

Pfizer Inc. named oncology research head Chris Boshoff as the drug company’s chief scientific officer while it works to fend ...

Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is ...

Pfizer (PFE) announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, ...

Pfizer (PFE) appoints Chris Boshoff as its new Chief Scientific Officer and President, R&D to replace the outgoing science ...

Replaces Mikael Dolsten (Il Sole 24 Ore Radiocor) - New York, 20 Nov - The US pharmaceutical Pfizer said that it has appointing Chris Boshoff as chief scientific officer and president in charge of ...